Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral Vancomycin Is an Effective Therapy in Adult Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Gastro hep advances·2026
Same author

Integration of Ustekinumab Biosimilars into Inflammatory Bowel Disease Care: Evidence, Implementation, and Patient-Centered Considerations.

Advances in therapy·2026
Same author

Electronic Health Record Burden Among Gastroenterology Providers in a Large Tri-state Tertiary Referral Center.

Digestive diseases and sciences·2026
Same author

Long-Term Infant Outcomes After In Utero Biologic Exposure: Results From the Pregnancy Inflammatory Disease Neonatal Outcomes Registry.

The American journal of gastroenterology·2026
Same author

Menopause and inflammatory bowel disease: more questions than answers.

The lancet. Gastroenterology & hepatology·2026
Same author

Hyperbaric Oxygen Therapy in the Management of Refractory Perianal Crohn's Disease.

Journal of clinical medicine·2025
Same journal

Update on the Management of Pregnant Patients With Inflammatory Bowel Disease.

Gastroenterology & hepatology·2026
Same journal

Management of Granulomatous Hepatitis.

Gastroenterology & hepatology·2026
Same journal

Update on Pregnancy in Inflammatory Bowel Disease.

Gastroenterology & hepatology·2026
Same journal

Strategies for Improving Hepatocellular Carcinoma Surveillance Rates.

Gastroenterology & hepatology·2026
Same journal

Managing the Diagnostic and Therapeutic Challenges of Irritable Bowel Syndrome.

Gastroenterology & hepatology·2026
Same journal

Raising the Bar on Risk Reduction in Post-ERCP Pancreatitis Prevention.

Gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: May 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Overcoming adherence issues in ulcerative colitis.

Sunanda V Kane1

  • 1Dr. Kane is Associate Professor of Medicine in the Division of Gastroenterology and Hepatology at the Mayo Clinic in Rochester, Minnesota.

Gastroenterology & Hepatology
|October 1, 2011
PubMed
Summary
This summary is machine-generated.

Patient adherence to ulcerative colitis (UC) medication is crucial for managing flares. Improving adherence requires healthcare provider education and exploring higher-strength 5-aminosalicylic acid (5-ASA) options to simplify treatment regimens.

Keywords:
5-ASAAdherenceconvenienceulcerative colitis

More Related Videos

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Related Experiment Videos

Last Updated: May 28, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Patient Adherence Research

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease requiring continuous medication.
  • Patient nonadherence to prescribed UC therapies is a significant clinical challenge.
  • Understanding reasons for nonadherence is vital for effective disease management.

Purpose of the Study:

  • To review real-world studies on patient adherence to 5-aminosalicylic acid (5-ASA) therapy for UC.
  • To identify common reasons for medication nonadherence in UC patients.
  • To explore strategies for improving patient adherence to 5-ASA treatment.

Main Methods:

  • Systematic review of clinical and community studies on 5-ASA adherence in ulcerative colitis.
  • Analysis of patient-reported reasons for nonadherence.
  • Evaluation of potential interventions to enhance medication adherence.

Main Results:

  • Patient nonadherence to 5-ASA therapy is prevalent in ulcerative colitis management.
  • Reasons for nonadherence are diverse and not consistently identified across studies.
  • No single patient group is consistently identified as high-risk for nonadherence.

Conclusions:

  • Improving adherence to ulcerative colitis therapy is complex and requires multifaceted strategies.
  • Healthcare providers should educate patients on continuous therapy importance and discuss adherence barriers.
  • Higher-strength 5-ASA formulations may improve adherence by simplifying dosing regimens.